Displaying 1 - 54 of 54 tests
ALK-1 (for heme cases)The ALK1 (ALK1 cline) antibody labels normal human ALK protein and the NPM-ALK chimeric protein, and is a useful tool for the identification of the subgroup of anaplastic large-cell lymphomas (ALCL) that are ALK positive. Immunohistochemistry (IHC)
B-Cell Gene Rearrangement

Detection of clonal IgH gene rearragements by PCR of IgH framework regions 1, 2, 3 and joining regions. In addition, Ig Kappa gene rearrangement analysis is performed using specific oligonucleotides recognizing the Vk, intragenic and Jk regions. Testing is approved for specimens from the state of New York.

Molecular
B-Cell Lymphoma Follow-Up Flow Panel

Available as global and tech-only. Please provide clinical history including the time after treatment. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Clients who decline full phenotyping and order a global or push-to-global Follow-Up Panel are requested to provide details of the diagnosis by submitting at least one of the following: previous flow cytometry report, previous pathology report, and/or clinical history notes. Markers are CD5, CD10, CD11c, CD19, CD20, CD23, CD45, FMC-7, kappa, and lambda.

Flow Cytometry
BCL1/Cyclin D1BCL1/Cyclin D1 is a nuclear protein detectable in formalin-fixed, paraffin-embedded (FFPE) sections and is found in the majority of mantle cell lymphomas. Hairy cell leukemia and plasmacytoma may also express BCL1 with a weaker signal. BCL1 is an oncogene acting as a cell cycle regulator possibly by mediating the growth stimulatory effects of hormone receptor signaling. It has been found to play a major role in both breast and prostate tumorigenesis. Nuclear overexpression of BCL1 has been shown to increase the chance of prostate cancer metastasis to bone, and has been associated with poor prognosis. High nuclear expression of BCL1 is usually associated with poor prognosis. Immunohistochemistry (IHC)
BCL2B-cell lymphoma 2 (BCL2) was the first of the translocation-associated proteins to be identified in lymphoma. Most cases of follicular lymphoma have a [t(14;18)] translocation, resulting in BCL2 overexpression. Overexpression of BCL2 in activated diffuse B-cell lymphoma may predict disease progression. BCL2 is also expressed in a wide range of other neoplasms. Immunohistochemistry (IHC)
BCL6BCL6 antibody stains the germinal center cells in lymphoid follicles, the follicular cells and interfollicular cells in follicular lymphoma, a subset of diffuse large B-cell lymphomas, and Burkitt lymphoma, as well as the majority of Reed-Sternberg cells in nodular lymphocyte predominant Hodgkin lymphoma. In contrast, BCL6 rarely stains mantle cell lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma. BCL6 expression is seen in approximately half of CD30+ anaplastic large cell lymphomas but is absent in other peripheral T-cell lymphomas. Immunohistochemistry (IHC)
BCL6 (3q27)Probes: BCL6 (3q27)
Disease(s): Diffuse large B-cell lymphoma, NHL
FISH
BTK Inhibitor Primary Susceptibility Panel

Concurrent analysis of the following by bi-directional sequencing: CARD11 exons 5 and 6, CD79B exon 5 including common Y196 mutations, CXCR4 C-terminus region, and MYD88 exon 5 including the L265P mutation.

Molecular
CD10CD10, also known as Common Acute Lymphocytic Leukemia Antigen (CALLA), is expressed in early lymphoid progenitors and normal germinal center cells. It is almost always present on the surface of precursor B-lymphoblastic and Burkitt lymphomas and much less frequently on precursor T-lymphoblastic leukemia-lymphoma. Many follicular lymphoma and some diffuse large B-cell lymphomas, along with multiple myeloma are positive. CD10 is also present on breast myoepithelial cells, bile canaliculi, fibroblasts and with especially high expression on the brush border of kidney and gut epithelial cells. CD10 is also a good marker of endometrial stomal sarcoma. Immunohistochemistry (IHC)
CD19CD19 recognizes a 95kD cell surface glycoprotein which is expressed by cells of the B-cell lineage and follicular dendritic cells. CD19 is a co-receptor of CD21and is an important signal transduction molecule which is involved in the regulation of B-lymphocyte development, activation and differentiation. CD19 may provide useful diagnostic information for the study of B-lymphoproliferative disorders. Immunohistochemistry (IHC)
CD20Normal cell expression of CD20 is found on most B-cells (after CD19 and CD10 expression, before CD21/22 expression and surface immunoglobulin expression) and expression is retained on mature B-cells until plasma cell development, as well as ollicular dendritic cells. In diseased cells, there is positive staining on most B-cell lymphomas, come pre-acute B lymphoblastic leukemia/ lymphoblastic lymphoma (B-ALL/LBL); lymphocyte predominant Hodgkin lymphoma, dimly expressed in T-cells (benign and neoplastic), and spindle cell thymomas. Rixtuximab treated patients may lose CD20 positivity in B cell lymphomas. Immunohistochemistry (IHC)
CD22CD22 expression is restricted to normal and neoplastic B-cells and is absent from other hemopoietic cell types. In B-cell ontogeny, CD22 is first expressed in the cytoplasm of pro-B and pre-B-cells and on the surface as B-cells mature to become IgD+. It is not expressed by plasma cells. CD22 is found highly expressed in follicular, mantle and marginal zone B-cells, while germinal center B-cells are relatively weak. Its expression roughly parallels that of CD19. It is strongly expressed in hairy cell leukemia. Immunohistochemistry (IHC)
CD3The CD3 antigen is first detectable in early thymocytes and its appearance probably represents one of the earliest signs of commitment to the T-cell lineage. It has a cytoplasmic expression at early T-cell differentiation, then membranous expression. CD3 is the most specific T-cell antibody. CD3 is expressed in normal thymocytes, peripheral T-cells, NK cells, and Purkinje cells of cerebellum. In diseased cells, CD3 stains most T-cell lymphomas. Only rare B cell lymphomas may be positive for CD3. Immunohistochemistry (IHC)
CD30CD30 is a lymphocyte activation antigen, related to tumor necrosis factor. It is expressed in activated B-, T- and NK cells. Positive staining is seen in infectious mononucleosis, lymphocytes infected with HIV, HTLV-1, EBV, HHV8 or hepatitis B, Reed-Sternberg cells, anaplastic large cell lymphomas (90%), lymphomatoid papulosis, peripheral T-cell lymphomas, and embryonal cell tumors. Immunohistochemistry (IHC)
CD43/FMC-7 Companion Add-On Flow PanelAvailable as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are CD43, CD3, CD22, CD36, FMC-7 and CD45 (6 abs).
CD5CD5, a transmembrane protein, is found on most thymocytes and immature peripheral T-cells. It stains normal B-cells of mantle zone of spleen and lymph nodes, B-cells in peritoneal and pleural cavities, and almost all T-cells. In a fetus, most B-cells in spleen and cord blood are CD5 positive. It stains B-cell chronic lymphocytic leukemia/ small lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL), hairy cell leukemia (HCL), most T-malignancies, and most thymic carcinomas. CD5 is usually negative in spindle cell thymoma. Immunohistochemistry (IHC)
CD79aCD79a first appears at the pre B-cell stage and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B-cell type, B-cell lines, B-cell lymphomas, and in some myelomas. It is not present in myeloid cells or T-cells. Immunohistochemistry (IHC)
CD79B Mutation Analysis

Bi-directional sequencing of exon 5 of the CD79B gene which includes detection of the common Y196 mutations. Testing is available separately or as part of the NeoTYPE™ Lymphoma Profile.

Molecular
cMETThe cMET tyrosine kinase receptor, normally expressed by epithelial cells, is overexpressed and amplified in a variety of human tumors, including non-small cell lung carcinoma (NSCLC). High levels of intratumor cMET expression have been associated with a more aggressive biology and a worse prognosis in NSCLC. Engelman et al. reported that cMET amplification induced resistance to gefitinib in a gefitinib-sensitive lung cancer cell line. Moreover, cMET inhibition with a cMET tyrosine kinase inhibitor (PHA-665,752) restored gefitinib sensitivity. Immunohistochemistry (IHC)
cMyccMyc protein is a transcription factor localized to the nucleus of the cell. Amplification of the cMyc gene has been found in several types of human tumors.

cMyc is amplified in 20-30% of breast cancer cases and is associated with HER-2 amplification and poor outcome. In Burkitt’s lymphoma, 90% of tumors have translocation of cMyc or variants. cMyc protein (>50%) is seen in a subset of cases of diffuse large B-cell lymphoma (DLBCL) and is correlated with Myc rearrangement. It is also positive in radiation-associated angiosarcoma.

Immunohistochemistry (IHC)
cRELInactive cREL resides in the cytoplasm and translocates to the nucleus upon activation. Strong, homogeneous nuclear cREL staining has been observed in primary mediastinal large B-cell lymphoma whereas nuclear cREL expression is more variable in other forms of diffuse large B-cell lymphoma (DLBCL). Evaluation of cREL nuclear expression combined with germinal center B-cell (GCB) and non-GCB phenotyping by IHC may improve patient risk stratification in DLBCL. Immunohistochemistry (IHC)
DUSP22-IRF4 Rearrangement

Probes: DUPS22-IRF4 gene region at 6p25.3
Disease(s): Anaplastic Large Cell Lymphoma (ALCL), large B-cell lymphoma
 

FISH
EBER

This probe set labels all latent EBV-infected cells, including EBV-positive lymphoblastoid cell lines and EBV infected B-cell immunoblasts in infectious mononucleosis. It also reacts with EBV-associated undifferentiated nasopharyngeal carcinomas and with Reed-Sternberg cells in almost all EBV-associated Hodgkin lymphoma cases. Global interpretation is available on head and neck specimens only; tech-only testing is available for all samples.

In Situ Hybridization (ISH)
EBV (LMP1)This antibody reacts strongly with Epstein Barr Virus (EBV)-positive lymphoblastoid cell lines and EBV infected B-cell immunoblasts in infectious mononucleosis. It also reacts with some EBV-associated neoplasms, particularly EBV-associated Hodgkin lymphoma. Immunohistochemistry (IHC)
Erythroid-Mega Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are cCD41, cCD61, CD13, CD34, CD45, CD71,  CD117, and CD235a (8 markers).

Flow Cytometry
EZH2 Mutation Analysis

Bi-directional sequencing of exons 3-13 and 15-18 of the EZH2 gene.

Molecular
FOXP1FOX P1 (Forkheadbox-P1) is a transcription factor widely expressed in normal tissues. Its expression is commonly deregulated in malignancies. FOX P1 is differentially expressed in resting and activated B cells. FOX P1 expression has been demonstrated in a subset of diffuse large B-cell lymphomas (DLBCL) and is more common in the non-germinal center (non-GC), activated B-cell type. Loss of FOX P1 expression has been correlated with a poor prognosis in solid tumors, such as breast cancer. In contrast, high level expression of smaller isoforms of the FOX P1 protein identifies high risk patients with DLBCL. The study demonstrated a correlation between strong nuclear positivity and poor prognosis in a subset of patients with BCL2-positive, [t(14;18)]-negative, non-GC DLBCL. Immunohistochemistry (IHC)
GCET1The GCET1 gene codes for a serpin expressed in germinal center (GC) B-cells. GCET1 is highly restricted to a subset of GC B-cells and GC-derived lymphomas. It is preferentially expressed in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) with GC B-cell differentiation. Immunohistochemistry (IHC)
HGALHGAL is specifically expressed in the cytoplasm of germinal center B-cells, but is absent in mantle and marginal zone. This antibody is highly specific for germinal center B-cells and it is an ideal marker for the detection of germinal center-derived B-cell lymphomas. Immunohistochemistry (IHC)
High-Grade B-Cell Lymphoma Reflex FISH Panel (Non-New York)

Probes: MYC (8q24). If rearranged, reflex to concurrent BCL2 (18q21) and BCL6 (3q27).
Disease(s): B-cell lymphoma, double-hit lymphoma, triple-hit lymphoma

Note: This test is available on a global basis. Tech-only clients may order probes individually.

FISH
High-Grade/Large B-Cell Lymphoma Panel (NY and non-NY)

Probes: BCL6 (3q27) | MYC (8q24) | IgH/BCL2 t(14;18) | Optional probes: MYC/IgH/CEN8 t(8;14) [available to all clients] and BCL2 (18q21) [non-New York clients only]
Disease(s): B-cell lymphoma, double-hit lymphoma, triple-hit lymphoma

FISH
IgH (14q32)

Probes: IgH (14q32)
Disease(s): Lymphoma, NHL, multiple myeloma, MGUS

FISH
IgH Clonality/MRD by NGS

The IgH Clonality/MRD by NGS assay detects clonal populations of B-lymphocytes in a given patient sample through the analysis of the VDJ segment of the immunoglobulin heavy chain (IgH) gene. *Note - Baseline testing of the original primary sample will need to be performed prior to testing on new samples submitted for monitoring of minimal residual disease.

Molecular
Ki67

Ki67 is a nuclear protein that is expressed in proliferating cells. Ki67 is preferentially expressed during late G1, S, M, and G2 phases of the cell cycle, while cells in the G0 (quiescent) phase are negative for this protein. Increased proliferative activity is associated with more aggressive tumor and decreased disease-free survival period.
Note: Computer-assisted image analysis for Ki-67 is only validated for breast cancer and neuroendocrine carcinoma.

Immunohistochemistry (IHC)
LEF1LEF1 overexpression is highly associated with CLL/SLL among small B-cell lymphomas and may serve as a useful marker for diagnosis and differential diagnosis of the disease. Immunohistochemistry (IHC)
LMO2LMO2 protein is expressed in normal human germinal-center (GC) and GC-derived lymphomas. In addition, it is also expressed at high levels in endothelial cells, spleen, hematopoietic precursors, and a significant proportion of acute lymphoblastic and myeloid leukemias. In diffuse large B-cell lymphoma (DLBCL), LMO2 protein expression is aligned with GC markers HGAL, CD10 and BCL6, indicating a potential role for LMO2 in the prognostic stratification of DLBCL patients. It is rarely expressed in mature T, natural killer (NK) and plasma cell neoplasms and is absent from non-hematolymphoid tissues, except for endothelial cells. Immunohistochemistry (IHC)
MAL

MAL is a distinct molecular marker of primary mediastinal large B-cell lymphoma subtype among diffuse large B-cell lymphomas.

Immunohistochemistry (IHC)
MET (c-MET) Mutation Analysis

Bi-directional Sanger sequencing of MET is performed using PCR primers designed to target hotspot mutations in exons 14, 16, 17 and 19.

Molecular
MET FISHProbes: MET (7q31) | Centromere 7
Disease(s): Multiple solid tumor cancers including lung (NSCLC), gastric, esophageal, endometrial
FISH
MGMT Promoter Methylation Analysis

Bisulfite modification of tumor DNA and real-time PCR are used to quantify CpG methylation within the MGMT gene promoter. Percentage of methylated DNA (compared to total DNA) is reported for positive results.

Molecular
MUM1The MUM1 antibody is specific for the MUM1/IRF4 protein that is overexpressed in late plasma-cell-directed stages of B-cell differentiation. MUM1 is a powerful tool for understanding the histogenesis of B-cell lymphomas. MUM1 protein is an excellent marker for Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma in combination with CD30. Furthermore, MUM1 seems to be a marker of prognostic value since it has been found that the expression of MUM1 is associated with the poor prognosis of patients with diffuse large B-cell lymphoma (DLBCL). Immunohistochemistry (IHC)
MYD88 Mutation Analysis

Bi-directional sequencing of exon 5 of the MYD88 gene which includes detection of the common L265P mutation.

Molecular
NeoTYPE Lymphoma Profile

This test is performed by multiple methods to detect mutations in the following genes BCL1, BCL2, BRAF, CARD11, CD79B, EZH2, MYD88 and NRAS. The test is performed by sequencing the entire coding regions of the genes listed unless otherwise noted. BCL1/ IgH translocation t(11;14) is performed by real-time PCR and BCL2  t(14;18) is performed by fragment length analysis. Test orders include summary interpretation of all results together.

Molecular
Non-Hodgkin's Lymphoma (NHL) FISH Panel

Probes: ALK (2p23) | BCL6 (3q27) | MYC (8q24) | CCND1/IgH t(11;14) | IgH (14q32) | IgH/BCL2 t(14;18) | MALT1 (18q21)
Probes may be ordered separately.
Disease(s): NHL

FISH
PAX5Paired Box 5 (PAX5) is a B-cell specific activator protein (BSAP). In early stages of B-cell development, PAX5 influences the expression of several B-cell specific genes, such as CD19 and CD20. PAX5 is expressed primarily in pro-, pre-, and mature B-cells, but not in plasma cells. There is an excellent correlation between CD20 and PAX5 expression; however, anti-PAX5 exceeds the specificity and sensitivity of L26 (CD20) because of its earlier expression in B-cell differentiation and its ability to detect all committed B-cells, including classic Hodgkin lymphoma. It is very specific to B-cell lineage and does not stain T-cells. Immunohistochemistry (IHC)
Standard Leukemia/Lymphoma Panel - 24 markers

Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD13, CD14, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, kappa, and lambda.

Flow Cytometry
STAT3 Mutation Analysis

Bi-directional sequencing of STAT3 exons 13-21 encompassing the DNA binding and SH2 domains.

Molecular
T&B Tissue Flow Panel

Stand-alone test. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD23, CD34, CD38, CD45, CD56, kappa, and lambda (17 markers). 

Flow Cytometry
T-Cell Receptor Beta Gene Rearrangement

This test provides qualitative detection of monoclonal T-cell receptor (TCR) beta gene rearrangements by PCR and fragment analysis according to BIOMED-2 consensus primer design. This test may be ordered concurrently with or after negative results in our T-Cell Receptor Gamma Gene Rearrangement assay for gamma gene rearrangements to improve TCR rearrangement detection by ~5% in T-cell leukemias/lymphomas. 

Molecular
T-Cell Receptor Gamma Gene Rearrangement

Detection of clonal T-cell receptor gamma (TCRG) gene rearrangements by PCR of variable and joining regions. T-Cell Receptor Beta Gene Rearrangement is offered separately and may be added to this gamma gene test.

Molecular
TP53 Mutation Analysis

Bi-directional sequencing of TP53 exons 4-9.

Molecular
Tumor Mutation Burden

Tumor Mutation Burden (TMB) testing at NeoGenomics measures the number of non-synonymous DNA coding sequence changes per megabase of sequenced DNA. Testing is performed routinely within the NeoTYPE™ Discovery Profile, can be added to any of the NeoTYPE Solid Tumor Profiles, and is available as a stand-alone test. Results are reported as low, high intermediate, and high upper quartile in reference to the median genomic TMB value determined across a wide variety of tumor types in an internal validation study. TMB is also called tumor mutational burden or tumor mutation load (TML). 

Molecular
Universal Fusion/Expression Profile

The Universal Fusion/Expression Profile is a targeted RNA sequencing panel that utilizes next-generation sequencing (NGS) to detect all relevant fusion transcripts in 1,385 genes associated with hematologic or solid tumor cancers. It is especially useful for testing patients with rare diseases. Learn more about the Universal Fusion/Expression Profile. See the full 1,385 gene list here.

Molecular
Wright GiemsaSpecial stain. The Wright Giemsa stain is used to stain peripheral blood and bone marrow smears for study of blood cell morphology. Immunohistochemistry (IHC)